American CryoStem Corp. is engaged in the development, market, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. It focuses on clinical processing, commercial bio-banking, and application development for adipose tissue and adipose-derived stem cells; and also provides contract manufacturing services to physicians and other medical professionals that perform tissue transfer and other cellular therapy services, as well as offers professional services, including sterility, viability, cellular density, and growth assay analysis. The company was founded by Anthony Francis Dudzinski on November 18, 2008 and is headquartered in Eatontown, NJ.
Company profile
Ticker
CRYO
Exchange
Website
CEO
John S. Arnone
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
R & A Productions, Inc.
SEC CIK
Corporate docs
IRS number
264574088
CRYO stock data
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
11 Apr 24
NT 10-K
Notice of late annual filing
3 Jan 23
10-Q
2022 Q3
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
10-Q
2022 Q2
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-Q
2022 Q1
Quarterly report
22 Feb 22
NT 10-Q
Notice of late quarterly filing
14 Feb 22
10-K
2021 FY
Annual report
13 Jan 22
NT 10-K
Notice of late annual filing
29 Dec 21
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 21 | Sep 20 | Sep 19 | Sep 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.76 k | 2.76 k | 2.76 k | 2.76 k | 2.76 k | 2.76 k |
Cash burn (monthly) | 6.67 k | 384.33 | 125.61 k | 304.34 k | 41.01 k | 57.35 k |
Cash used (since last report) | 145.96 k | 8.41 k | 2.75 mm | 6.66 mm | 897.39 k | 1.26 mm |
Cash remaining | -143.20 k | -5.65 k | -2.75 mm | -6.66 mm | -894.63 k | -1.25 mm |
Runway (months of cash) | -21.5 | -14.7 | -21.9 | -21.9 | -21.8 | -21.8 |
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 0.00 | $0.00 |